Investigating the Role of Oncotype DX in the Treatment of Early Stage Luminal A Breast

被引：0
|
作者：
Hughes, L. [1 ]
Mcveigh, T. [1 ]
Keane, M. [2 ]
Sweeney, K. [1 ]
Kerin, M. [1 ]
机构：
[1] Natl Univ Ireland Galway, Discipline Surg, Galway, Ireland
[2] Galway Univ Hosp, Dept Oncol, Galway, Ireland
来源：
BRITISH JOURNAL OF SURGERY | 2015年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
1033
引用
收藏
页码：17 / 17
页数：1
相关论文
共 50 条
  • [31] Luminal subtypes vs. early Ki-67 response and Oncotype DX® in early breast cancer: WSG-ADAPT study
    Gluz, O.
    Nitz, U.
    Christgen, M.
    Kreipe, H.
    Kates, R. E.
    Kuemmel, S.
    Braun, M.
    Schumacher, C.
    Wuerstlein, R.
    Harbeck, N.
    BREAST, 2015, 24 : S104 - S105
  • [32] Evaluation Oncotype DX® 21-Gene Recurrence Score and clinicopathological parameters in early stage breast cancer
    Lashen, A. L.
    Toss, M. T.
    Fadhil, W. F.
    Oni, G. O.
    Madhusudan, S. M.
    Rakha, E. R.
    JOURNAL OF PATHOLOGY, 2023, 261 : S10 - S10
  • [33] Prediction of Oncotype DX Recurrence Score by Evaluating the Peritumoral Tumor Budding in Early-stage Breast Carcinoma
    Chu, Jinah
    Do, Jeongeun
    Do, Sung-Im
    Kim, Hyun-Soo
    ANTICANCER RESEARCH, 2023, 43 (12) : 5563 - 5571
  • [34] Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer
    Jon Whitney
    German Corredor
    Andrew Janowczyk
    Shridar Ganesan
    Scott Doyle
    John Tomaszewski
    Michael Feldman
    Hannah Gilmore
    Anant Madabhushi
    BMC Cancer, 18
  • [35] Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER plus breast cancer
    Whitney, Jon
    Corredor, German
    Janowczyk, Andrew
    Ganesan, Shridar
    Doyle, Scott
    Tomaszewski, John
    Feldman, Michael
    Gilmore, Hannah
    Madabhushi, Anant
    BMC CANCER, 2018, 18
  • [36] Oncotype DX Risk Recurrence Score and Total Mortality for Early-Stage Breast Cancer by Race/Ethnicity
    Moore, Jaleesa
    Wang, Fei
    Pal, Tuya
    Reid, Sonya
    Cai, Hui
    Bailey, Christina E.
    Zheng, Wei
    Lipworth, Loren
    Shu, Xiao-Ou
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2022, 31 (04) : 821 - 830
  • [37] Impact of Oncotype DX Recurrence Score on Breast Cancer Prognostic Stage Group
    Breaux, Andrea C.
    Sanders, Mary Ann
    Turner, Bradley M.
    Wu, Xiaoyong
    Rai, Shesh N.
    Riley, Elizabeth C.
    MODERN PATHOLOGY, 2018, 31 : 52 - 52
  • [38] Impact of Oncotype DX Recurrence Score on Breast Cancer Prognostic Stage Group
    Breaux, Andrea C.
    Sanders, Mary Ann
    Turner, Bradley M.
    Wu, Xiaoyong
    Rai, Shesh N.
    Riley, Elizabeth C.
    LABORATORY INVESTIGATION, 2018, 98 : 52 - 52
  • [39] Requesting, Treatment and Outcomes Following Oncotype DX Testing in Breast Cancer
    Issa, H.
    Seward, J.
    Meara, N.
    BRITISH JOURNAL OF SURGERY, 2021, 108
  • [40] Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
    Caitlin Taylor
    Jane Meisel
    Aimee J. Foreman
    Christy Russell
    Dipankar Bandyopadhyay
    Xiaoyan Deng
    Lisa Floyd
    Amelia Zelnak
    Harry Bear
    Ruth O’Regan
    Breast Cancer Research and Treatment, 2023, 199 : 91 - 98
12345